The treatment with pasireotide in Cushing's disease: effects of long-term treatment on tumor mass in the experience of a single center

What Was Tested

Researchers studied Somatostatin and ACTH (Corticotropin) in this randomized controlled trial publication.

Pasireotide is the first medical therapy officially approved for the treatment of adult patients with Cushing's disease (CD) who experienced a failure of pituitary surgery or are not candidates for surgery and require medical therapeutic intervention.

The current study aimed at investigating the effects of long-term treatment with pasireotide (up to 24 months) on tumor mass in a group of patients with CD, participating to a phase III study.

Who Took Part

PubMed indexes the participants as teenagers, young adults, adults and middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a randomized study.

The participants were allocated by chance, so the Somatostatin group and the comparison group should start out alike.

A time span of 24 months appears in the methods.

What Was Measured

These eight patients were subjected to the evaluation of pituitary tumor volume by pituitary MRI, together with the evaluation of urinary cortisol levels, at baseline and every 6 months for the entire period of treatment.

The subject headings attached to it are Pituitary ACTH Hypersecretion and Somatostatin.

Author keywords: ACTH-secreting pituitary tumor, Cushing’s disease, Cushing’s syndrome, Pasireotide, Somatostatin analogs and Tumor mass.

What This Means in Plain Language

The paper is a randomized study of Somatostatin and ACTH (Corticotropin) over 24 months.

The publication is from 2015 (Endocrine), a journal based in United States.

More context: the Somatostatin compound page and the ACTH (Corticotropin) compound page, all human trials.